Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × ALK-positive Advanced Tumors × ceritinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 7 Neoplasms 3 Neuroblastoma 2 Lung Neoplasms 2 Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1 Rhabdomyosarcoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 ALK-positive Advanced Tumors 1

Interventions

ceritinib 1 Warfarin 1 Midazolam 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02422589 2020-12-19

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Novartis

Phase 1 Completed

ALK-positive Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡